cabozantinib,nivolumab,ipilimumab
bms,exelixis
['triplet,(-triplete)', 'rcc,(-irccs),(-srcc),(-urcc)', 'cosmic313']
overall, at #esmo22, #cosmic313 showed an improvement in pfs vs doublet standard in patients with advanced imdc intermediate- or poor-risk #rcc. there was an incremental difference in response and increased toxicity with the triplet regimen. we look forward to seeing os data 
CME experts Sara Fagerlie, PhD, CHCP & Mindy Tanzola, PhD have joined forces at Front Row to help clinicians & educators manage the oncology information deluge